Astrazeneca (AZN) Equity Income (2014 - 2026)

Astrazeneca has reported Equity Income for 13 years, with the latest figure at -$10.0 million in Q2 2026.

• On a quarterly basis, Equity Income changed 0.0% year-over-year to -$10.0 million in Q2 2026; TTM through Jun 2026 was -$19.0 million, a 26.92% increase from a year earlier, with the FY2025 full-year figure at -$7.0 million, up 75.0% from the prior year.
• Equity Income was -$10.0 million for Q2 2026 at Astrazeneca, up from -$12.0 million in the prior quarter.
• The five-year high for Equity Income was $10.0 million in Q3 2025, with the low at -$13.0 million in Q1 2024.
• Average Equity Income over 5 years is -$5.1 million, with a median of -$6.0 million recorded in 2022.
• The sharpest annual moves came in 2023 and 2025: Equity Income slumped 1200.0% in 2023, then soared 350.0% in 2025.
• Over 5 years, Equity Income stood at -$1.0 million in 2022, then plunged by 1000.0% to -$11.0 million in 2023, then jumped by 54.55% to -$5.0 million in 2024, then sank by 40.0% to -$7.0 million in 2025, then plunged by 42.86% to -$10.0 million in 2026.
• The last three Equity Income figures came in at -$10.0 million (Q2 2026), -$12.0 million (Q1 2026), and -$7.0 million (Q4 2025), per Business Quant data.